T-cell receptor alpha-beta (TCR alpha-beta) (TCRαβ or TCR ab)

The **T-cell receptor alpha-beta (TCRαβ)** is a heterodimeric, membrane-bound protein complex expressed on the surface of the majority of T lymphocytes (about 95% in humans)[3][7]. It consists of two chains, alpha and beta (encoded by TRA and TRB), each with variable and constant immunoglobulin-like domains, and relies on gene rearrangement (V(D)J recombination) for receptor diversity[1][3][7]. The TCRαβ complex, together with invariant CD3 signaling components, is responsible for the specific recognition of antigenic peptides presented by major histocompatibility complex (MHC) molecules on other cells, ultimately initiating the signaling pathways required for T cell activation and the adaptive immune response[1][3][5][7]. Through accessory interactions with co-receptors and CD3 chains containing immunoreceptor tyrosine-based activation motifs (ITAMs), TCR engagement leads to intracellular signal transduction involving kinases such as Lck and Zap70, and downstream cellular activation[3][5]. Malfunctions or therapeutic manipulations of TCRαβ can play key roles in cancer, autoimmunity, infection, and immunodeficiency[5][7]. This receptor is not itself enzymatic or directly druggable, but it is the focus of much immunotherapy (engineered TCR therapeutics, T cell diagnostics) and fundamental immunological research[5][7].

Other names

αβ T-cell receptorTCRαβT-cell antigen receptor alpha-betaT-cell receptor alpha/betaα:β TCRalpha-beta TCRTCR-αβ

Inhibition of TCR-mediated signal transduction (immunosuppressants, e.g., calcineurin pathway inhibitors)[5]. Therapeutic TCR redirection (engineered TCR or TCR-mimic therapeutics)[5]. Depletion of T cells via antibody binding to TCR/CD3 complex[7].